Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of 68Ga Labeled HER2 Affibody Analogues in Healthy Volunteers and Patients With Breast or Gastric Tumors

NCT05411432 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT05411432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of 68Ga Labeled HER2 Affibody Analogues in Healthy Volunteers and Patients With Breast or Gastric Tumors
Lead sponsor
Xijing Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
June 1, 2022
Completion date
December 1, 2023
Enrollment
56 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer and gastric cancer